Long-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs

Last updated: September 30, 2024
Sponsor: Institut Rafael
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Cancer

Treatment

questionnaires

Clinical Study ID

NCT06317714
IR-2023/0002
2023-A02233-42
  • Ages > 18
  • All Genders

Study Summary

Currently, aspects related to the effects of anticancer treatments and the quality of life of patients and their needs are still poorly documented at the Rafael Institute. Thus this study will meet a dual objective: (1) the establishment of a registry to collect data on the safety and effectiveness of innovative and expensive anticancer drugs when administered in real life and (2) a measurement quantitative quality of life of patients treated with these drugs.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age equal to or greater than 18 years (adult)

  • Patients treated with an anticancer drug included in the list ofinnovative/expensive therapies (protocol appendix)

  • Patients benefiting from non-pharmacological treatment at the Rafael Institute

  • Who understands the French language

Exclusion

Exclusion Criteria:

  • < 18 years old

  • Patient deprived of liberty, under guardianship or unable to give consent

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: questionnaires
Phase:
Study Start date:
March 08, 2024
Estimated Completion Date:
March 08, 2027

Study Description

In France, the promotion of more patient-centered medicine is among the priorities identified by the High Authority for Health in its 2024 strategic project. The patient-centered approach is based on a partnership relationship with the patient, their loved ones, and the healthcare professional or a multi-professional team to built together the best option of care.

In this approach, the Rafael Institute was created with the objective of caring for people and not simply pathologies. Initiated around the problem of cancer and the harmful effects of its treatments, the Rafaël Institute offers personalisation of care and continuity of care over time by providing monitoring and support to the patient by a multi-professional and multidisciplinary team. Thus, maintaining quality of life constitutes one of the objectives of the therapeutic management of patients with cancer.

Although modern oncological treatments have today enabled real advances on the biomedical level, they often have side effects that must be taken into account for the overall assessment and management of patients. Although most anticancer therapies have a negative impact on the patient's quality of life, this does not always reflect the occurrence of toxicity.

Since the 1990s, quality of life has been strongly associated with survival. Patients with high overall quality of life live significantly longer than patients with low overall quality of life.

The relationship between symptoms, their intensity and quality of life is essential to study to understand the perceived impact of treatments and optimize their use in daily practice.

The effects of treatment and quality of life can be assessed precisely and reliably using standardized and validated self-questionnaires. Completed by patients, they make it possible to measure the qualitative aspects directly linked to their health and to take into account their subjective perception of their state of health.

Connect with a study center

  • Institute Rafaël

    Levallois Perret, Institut Rafael 92300
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.